CEL-SCI to Present at 18th Annual BIO CEO &
Investor Conference

February 03, 2016 09:00 AM Eastern Time

VIENNA, Va.--(EON: Enhanced Online News)--CEL-SCI Corporation (NYSE MKT: CVM) announced that Geert Kersten,
Chief Executive Officer, will be presenting at the 18th
Annual BIO CEO & Investor Conference on Tuesday, February 9, 2016 at
11:00 a.m. Hosted by the Biotechnology Industry Organization (BIO), the
18th Annual BIO CEO & Investor Conference will take place
February 8-9 at the Waldorf Astoria in New York City.

A live audio webcast of the presentation and replay will be available
under the investor relations section of CEL-SCI's website at www.cel-sci.com/investor_relations.html.
The replay of the presentation will be available approximately 1 hour
after the presentation and is accessible until May 8, 2016.

About the BIO CEO & Investor Conference

Now in its eighteenth year, the BIO CEO & Investor Conference is the
largest investor conference focused on established and emerging publicly
traded and select private biotech companies. Each year this conference
provides a neutral forum where institutional investors, industry
analysts, and senior biotechnology executives have the opportunity to
shape the future investment landscape of the biotechnology industry.

About CEL-SCI Corporation

CEL-SCI is a Phase 3 immunotherapy company with platform technologies
that can potentially treat a variety of cancers and viral diseases. We
believe that one must activate the immune system BEFORE radiation and
chemotherapy, and even before surgery, to achieve the best results in
the greatest number of patients. CEL-SCI is conducting a Phase 3 trial
in 24 countries of Multikine (Leukocyte Interleukin Injection) for the
treatment of head and neck cancer, which accounts for about 6% of
cancers globally and a $6 billion market. Almost 700 patients are
already enrolled in this study. CEL-SCI is also testing Multikine with
the U.S. Navy in HIV infected patients with HPV related diseases.
CEL-SCI has development partnerships with Teva Pharmaceuticals, Orient
EuroPharma of Taiwan, Ergomed and the NIH. The Company operates its own
75,000 sq. ft. manufacturing facility and produces Multikine for its
clinical trials. When fully built out, this facility will have the
capacity to supply about $3 billion worth of Multikine annually. CEL-SCI
is also developing its pre-clinical L.E.A.P.S. (Ligand Epitope Antigen
Presentation System) technology as a potential vaccine for the treatment
of rheumatoid arthritis.

The Company has operations in Vienna, Virginia, and in/near Baltimore,
Maryland.